Loading clinical trials...
Loading clinical trials...
A Randomized, Placebo-Controlled Crossover Trial to Assess the Safety and Efficacy of NB-001 in Children and Adolescents With 22q11 Deletion Syndrome
Conditions
Interventions
NB-001
Placebo
Locations
4
United States
Children's Hospital Colorado
Aurora, Colorado, United States
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States
Seattle Children's Hospital
Seattle, Washington, United States
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
Start Date
February 10, 2022
Primary Completion Date
June 1, 2023
Completion Date
June 9, 2023
Last Updated
February 10, 2025
Lead Sponsor
Nobias Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions